AcuraStem

Investors · 1

KE

Keiretsu ForumSan Francisco · $250K – $2M

$3.9M disclosed across 3 of 6 rounds · 2018–2026

▶$5MofferedJun 2026 · Biotechnology

Rule 506(b)

CIRM Awards AcuraStem $7.5 Million in Grant Funding to Advance AS-241 Toward a First-in-Human Trial for ALS and FTDprnewswire.com · Apr 2026 · press release

Officers, directors & promoters on the filing

• Samuel AlworthExecutive Officer, Director
• Qing Liu-MichaelDirector
• Paul AugustDirector
• Marcel van der BrugExecutive Officer
• Justin IchidaDirector

Offering amount

$5M

Minimum investment

$10K

Incorporated

Corporation, Delaware

Federal exemptions

06b

Full filing on SEC EDGAR ↗

▶$3.1MraisedNov 2022 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

• Justin IchidaDirector
• Samuel AlworthExecutive Officer, Director
• Paul AugustDirector
• Qing Liu-MichaelDirector

Offering amount

$3.1M

Amount sold

$3.1M

Minimum investment

$25K

First sale

Nov 2022

Incorporated

Corporation, Delaware

Federal exemptions

06b

Full filing on SEC EDGAR ↗

▶$400KraisedNov 2022 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

• Paul AugustDirector
• Justin IchidaDirector
• Samuel AlworthExecutive Officer, Director
• Qing Liu-MichaelDirector

Offering amount

$3.5M

Amount sold

$400K

Minimum investment

$25K

First sale

Nov 2022

Incorporated

Corporation, Delaware

Federal exemptions

06b

Full filing on SEC EDGAR ↗

▶$380KraisedJun 2019 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

• Samuel AlworthExecutive Officer, Director
• Paul AugustDirector
• Justin IchidaExecutive Officer, Director
• Qing Liu-MichaelDirector

Offering amount

$2M

Amount sold

$380K

Minimum investment

$25K

Proceeds to insiders

$150K

First sale

Jun 2018

Incorporated

Corporation, Delaware, 2016

Federal exemptions

06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

VE

Verastem12 shared keywordsVerastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients. The company focuses on oncology therapeutics including small molecules and monoclonal antibodies targeting pathways such as RAS, KRAS, and immune modulation.

BI

Bioworld12 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

QU

Quralis10 shared keywordsQurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms. The company was founded by neuroscientists from Harvard to translate emerging discoveries about disease pathways into treatment breakthroughs for ALS patients.

BI

BioStem Technologies9 shared keywordsBioStem Technologies develops human amniotic membrane allograft products for advanced surgical care and wound care, used as adjunct treatments for chronic and acute wounds. Its offerings use cryopreserved, hydrated, and dehydrated membrane technologies for clinical and veteran patient populations.

Companies competing with AcuraStem for the same Google search keywords, organic and paid, via search-intersection analysis.

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.